The Treatment of Painful Diabetic Neuropathy
- 1 June 2022
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 18 (5) , 1
Abstract
: Painful diabetic peripheral neuropathy (painful-DPN) is a highly prevalent and disabling condition, affecting up to one-third of patients with diabetes. This condition can have a profound impact resulting in a poor quality of life, disruption of employment, impaired sleep, and poor mental health with an excess of depression and anxiety. The management of painful-DPN poses a great challenge. Unfortunately, currently there are no Food and Drug Administration (USA) approved disease-modifying treatments for diabetic peripheral neuropathy (DPN) as trials of putative pathogenetic treatments have failed at phase 3 clinical trial stage. Therefore, the focus of managing painful- DPN other than improving glycaemic control and cardiovascular risk factor modification is treating symptoms. The recommended treatments based on expert international consensus for painful- DPN have remained essentially unchanged for the last decade. Both the serotonin re-uptake inhibitor (SNRI) duloxetine and α2δ ligand pregabalin have the most robust evidence for treating painful-DPN. The weak opioids (e.g. tapentadol and tramadol, both of which have an SNRI effect), tricyclic antidepressants such as amitriptyline and α2δ ligand gabapentin are also widely recommended and prescribed agents. Opioids (except tramadol and tapentadol), should be prescribed with caution in view of the lack of definitive data surrounding efficacy, concerns surrounding addiction and adverse events. Recently, emerging therapies have gained local licenses, including the α2δ ligand mirogabalin (Japan) and the high dose 8% capsaicin patch (FDA and Europe). The management of refractory painful-DPN is difficult; specialist pain services may offer off-label therapies (e.g. botulinum toxin, intravenous lidocaine and spinal cord stimulation), although there is limited clinical trial evidence supporting their use. Additionally, despite combination therapy being commonly used clinically, there is little evidence supporting this practise. There is a need for further clinical trials to assess novel therapeutic agents, optimal combination therapy and existing agents to determine which are the most effective for the treatment of painful-DPN. This article reviews the evidence for the treatment of painful-DPN, including emerging treatment strategies such as novel compounds and stratification of patients according to individual characteristics (e.g. pain phenotype, neuroimaging and genotype) to improve treatment responses.Keywords
This publication has 380 references indexed in Scilit:
- Gain-of-function Na v 1.8 mutations in painful neuropathyProceedings of the National Academy of Sciences, 2012
- Altered Excitation-inhibition Balance in the Brain of Patients with Diabetic NeuropathyAcademic Radiology, 2012
- Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patchBritish Journal of Anaesthesia, 2011
- Capsaicin induces degeneration of cutaneous autonomic nerve fibersAnnals of Neurology, 2010
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEuropean Journal of Neurology, 2010
- Role of voltage-gated calcium channels in ascending pain pathwaysBrain Research Reviews, 2009
- Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transportersPain, 2008
- Opioids and the treatment of chronic pain: Controversies, current status, and future directions.Experimental and Clinical Psychopharmacology, 2008
- Tricyclic antidepressant pharmacology and therapeutic drug interactions updatedBritish Journal of Pharmacology, 2007
- painDETECT: a new screening questionnaire to identify neuropathic components in patients with back painCurrent Medical Research and Opinion, 2006